EST Cathie Wood’s ARK Investment bought 176K shares of Crispr Therapeutics (CRSP) todayDon't Miss our Black Friday Offers:Discover the ...

But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...

It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.

Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.

Today’s mass-produced tomatoes often grow to palm-sized proportions, but their naturally occurring ancestors were far smaller ...

Rotten tomatoes no more: growing sweeter tomatoes is possible by editing just two of the fruit’s genes. Deleting the genes ...

CRISPR Therapeutics ( CRSP -5.91%) made a name for itself by pioneering advanced gene therapies made with technologies that didn't exist a generation ago. Now, its challenge is to build on its prior ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on CRSP: CRISPR Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Life Sciences Center (LSC) have discovered a unique way for cells to silence specific genes without cutting DNA. This ...

In recent years, scientists have created a range of new methods based on CRISPR-Cas technology for precisely editing the ...